{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:39:50Z","timestamp":1792643990917,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404447"],"award-info":[{"award-number":["82404447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82660799"],"award-info":[{"award-number":["82660799"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB216131"],"award-info":[{"award-number":["20232BAB216131"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20262BAC240152"],"award-info":[{"award-number":["20262BAC240152"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119298","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:41:15Z","timestamp":1788417675000},"page":"119298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel 7,8-dihydro-1H-purine derivatives as potent dual DNA-PK\/HDAC inhibitors against solid tumors"],"prefix":"10.1016","volume":"320","author":[{"given":"Zhihao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpeng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119298_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jmcb\/mjq057","article-title":"Genomic instability and cancer: an introduction","volume":"3","author":"Shen","year":"2011","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119298_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119298_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.dnarep.2009.04.018","article-title":"Human DNA damage response and repair deficiency syndromes: linking genomic instability and cell cycle checkpoint proficiency","volume":"8","author":"Kerzendorfer","year":"2009","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2026.119298_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.molonc.2011.07.006","article-title":"DNA damage response, genetic instability and cancer: from mechanistic insights to personalized treatment","volume":"5","author":"Bartek","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119298_bib5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119298_bib6","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1038\/s41467-023-42850-x","article-title":"Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1\/2 and RAD51","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119298_bib7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41580-020-00297-8","article-title":"The molecular basis and disease relevance of non-homologous DNA end joining","volume":"21","author":"Zhao","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119298_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119298_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1016-8478(23)15019-9","article-title":"DNA-dependent protein kinase complex: a multifunctional protein in DNA repair and damage checkpoint","volume":"13","author":"Lee","year":"2002","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ejmech.2026.119298_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.613","article-title":"The multifaceted functions of DNA-PKcs: implications for the therapy of human diseases","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.119298_bib11","doi-asserted-by":"crossref","first-page":"10780","DOI":"10.1093\/nar\/gks849","article-title":"Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress","volume":"40","author":"Liu","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119298_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2024.103689","article-title":"DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor olaparib in BRCA1\/2 deficient tumors","volume":"139","author":"Wang","year":"2024","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2026.119298_bib13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts","volume":"17","author":"Timme","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119298_bib14","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119298_bib15","first-page":"7545","article-title":"Inhibition of DNA-PK activity sensitizes A549 cells to X-ray irradiation by inducing the ATM-dependent DNA damage response","volume":"17","author":"Yang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2026.119298_bib16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/cas.12998","article-title":"Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair","volume":"107","author":"Sunada","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119298_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114401","article-title":"Discovery of novel 7,8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy","volume":"237","author":"Ding","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119298_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41416-025-03053-x","article-title":"The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human phase I\/IIa study","volume":"133","author":"Yap","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119298_bib20","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.2147\/CMAR.S208720","article-title":"First-in-human phase I study of A dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy","volume":"11","author":"Munster","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejmech.2026.119298_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1021\/acs.jmedchem.3c01338","article-title":"Discovery, optimization, and evaluation of potent and selective DNA-PK inhibitors in combination with chemotherapy or radiotherapy for the treatment of malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib26","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/acs.jmedchem.9b01684","article-title":"The discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor","volume":"63","author":"Goldberg","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib24","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-20-3701","article-title":"Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I IFN-dependent durable tumor control","volume":"27","author":"Nakamura","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119298_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1535-7163.MCT-21-0420","article-title":"The DNA-PK inhibitor AZD7648 sensitizes patient-derived ovarian cancer xenografts to pegylated liposomal doxorubicin and olaparib preventing abdominal metastases","volume":"21","author":"Anastasia","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119298_bib28","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-Human study of the ataxia telangiectasia and Rad3-Related (ATR) inhibitor Tuvusertib (M1774) as monotherapy in patients with solid tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119298_bib29","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.3390\/ijms25115629","article-title":"Effective radiosensitization of HNSCC cell lines by DNA-PKcs inhibitor AZD7648 and PARP inhibitors Talazoparib and Niraparib","volume":"25","author":"Mentzel","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119298_bib30","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/1535-7163.MCT-23-0681","article-title":"Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues","volume":"23","author":"Baker","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119298_bib31","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117601","article-title":"Design, synthesis and bioevaluation of novel hydrazide derivatives as enhancers of immunotherapy and DNA-damage response in antitumor therapy","volume":"291","author":"Hu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/15384101.2020.1867790","article-title":"DNA-PKcs inhibition impairs HDAC6-mediated HSP90 chaperone function on Aurora A and enhances HDACs inhibitor-induced cell killing by increasing mitotic aberrant spindle assembly","volume":"20","author":"Yu","year":"2021","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.119298_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118634","article-title":"Discovery of potent bifunctional small molecules targeting DNA-PK and HDAC6 with desirable pharmacokinetic properties for acute myeloid leukemia treatment","volume":"306","author":"Ding","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib36","first-page":"97","article-title":"Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method","volume":"6","author":"Zhang","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119298_bib37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2017.322","article-title":"Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma","volume":"32","author":"Ray","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119298_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119298_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejphar.2018.03.026","article-title":"A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer","volume":"828","author":"Dong","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119298_bib40","doi-asserted-by":"crossref","first-page":"12723","DOI":"10.1021\/acs.jmedchem.1c00762","article-title":"BAY-8400: a novel potent and selective DNA-PK inhibitor which shows synergistic efficacy in combination with targeted alpha therapies","volume":"64","author":"Berger","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib41","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1158\/0008-5472.CAN-19-1302","article-title":"HDAC6 inhibition synergizes with Anti-PD-L1 therapy in ARID1A-Inactivated ovarian cancer","volume":"79","author":"Fukumoto","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119298_bib42","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1021\/acs.jmedchem.3c02231","article-title":"Discovery of novel heterotricyclic compounds as DNA-dependent protein kinase (DNA-PK) inhibitors with enhanced chemosensitivity, oral bioavailability, and the ability to potentiate cancer immunotherapy","volume":"67","author":"Cheng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119298_bib43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.str.2007.12.014","article-title":"Cryo-EM structure of the DNA-dependent protein kinase catalytic subunit at subnanometer resolution reveals alpha helices and insight into DNA binding","volume":"16","author":"Williams","year":"2008","journal-title":"Structure"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:20:53Z","timestamp":1792642853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"alternative-id":["S0223523426007439"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119298","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel 7,8-dihydro-1H-purine derivatives as potent dual DNA-PK\/HDAC inhibitors against solid tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119298"}}